ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), today announced four appointments to its Board of Directors: ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat ...

Andrea Delbarba and Claudia Finetti of Bugnion SpA explain how supplementary protection certificates extend pharmaceutical ...

The FTSE 100 has opened lower, as predicted, dropping 19 points or 0.2% to 9,145. This is almost entirely due to a heavy ...

Fintel reports that on August 6, 2025, Leerink Partners initiated coverage of Xilio Therapeutics (NasdaqGS:XLO) with a ...

DelveInsight's CLK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.

On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ...

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced interim data from several cohorts from the ...

Earnings season continues as we highlight companies expected to report earnings the next trading day, helping investors prepare for the upcoming market action. Leading the charge are Square, Gilead ...

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...